MX2021005377A - Terapias dirigidas a cdcp1. - Google Patents

Terapias dirigidas a cdcp1.

Info

Publication number
MX2021005377A
MX2021005377A MX2021005377A MX2021005377A MX2021005377A MX 2021005377 A MX2021005377 A MX 2021005377A MX 2021005377 A MX2021005377 A MX 2021005377A MX 2021005377 A MX2021005377 A MX 2021005377A MX 2021005377 A MX2021005377 A MX 2021005377A
Authority
MX
Mexico
Prior art keywords
cdcp1
targeted therapies
cdcpl
methods
present disclosure
Prior art date
Application number
MX2021005377A
Other languages
English (en)
Inventor
Hui Liu
Lidia Mosyak
Eric M Bennett
Kimberly Ann Marquette
Lewis C Cantley
Isaac J Rondon
Stephen P Soltoff
Brooke M Emerljng
George Poulogiannis
Cindy M Hodakoski
Irina Apostolou
Brian Gaither Bates
Lioudmila G Tchistiakova
Edward Christian Rosfjord
Chao Bai Huang
Original Assignee
Beth Israel Deaconess Medical Ct Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Ct Inc filed Critical Beth Israel Deaconess Medical Ct Inc
Publication of MX2021005377A publication Critical patent/MX2021005377A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/915—Fusion polypeptide containing a motif for post-translational modification containing a motif for acylation

Abstract

La presente descripción proporciona materiales y métodos para la terapia dirigida a la proteína 1 que contiene el dominio CUB (CDCP1).
MX2021005377A 2018-11-09 2019-11-07 Terapias dirigidas a cdcp1. MX2021005377A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758442P 2018-11-09 2018-11-09
PCT/US2019/060276 WO2020097336A1 (en) 2018-11-09 2019-11-07 Cdcp1-targeted therapies

Publications (1)

Publication Number Publication Date
MX2021005377A true MX2021005377A (es) 2021-09-14

Family

ID=70612233

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005377A MX2021005377A (es) 2018-11-09 2019-11-07 Terapias dirigidas a cdcp1.

Country Status (8)

Country Link
US (1) US20220119545A1 (es)
EP (1) EP3876988A4 (es)
JP (1) JP7440509B2 (es)
CN (1) CN113382750A (es)
AU (1) AU2019376078A1 (es)
CA (1) CA3118542A1 (es)
MX (1) MX2021005377A (es)
WO (1) WO2020097336A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102225039B1 (ko) * 2018-12-17 2021-03-10 한국과학기술원 Cd8+ 메모리 t 세포 매개성 질환의 예방 또는 치료용 약학 조성물
WO2023134715A1 (zh) * 2022-01-12 2023-07-20 中国医学科学院阜外医院 心肌细胞的分离试剂和分离方法
WO2023246701A1 (zh) * 2022-06-20 2023-12-28 四川汇宇制药股份有限公司 一种抗体及其用途
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
CN1639185A (zh) * 2002-01-03 2005-07-13 斯克里普斯研究学院 癌相关表位
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US8716451B2 (en) * 2005-01-12 2014-05-06 Kyowa Hakko Kirin Co., Ltd Stabilized human IgG2 and IgG3 antibodies
US20070031419A1 (en) * 2005-06-30 2007-02-08 Applera Corporation Methods and compositions for treating diseases targeting CDCP1
CN101918447B (zh) * 2007-12-14 2014-06-11 布里斯托尔-米尔斯·斯奎布公司 人ox40受体的结合分子
EP2268672A1 (en) * 2008-03-12 2011-01-05 Imclone LLC Anti-tyrp1 antibodies
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
TW201113037A (en) * 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
US10706955B2 (en) * 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US9127056B2 (en) * 2011-10-17 2015-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
HUE049622T2 (hu) * 2014-04-25 2020-09-28 Rinat Neuroscience Corp Magas drog-töltöttségû ellenanyag-drog konjugátumok
KR20170075778A (ko) * 2014-10-27 2017-07-03 에이전시 포 사이언스, 테크놀로지 앤드 리서치 항-tim-3 항체
CN108884169B (zh) * 2016-01-22 2022-03-22 默沙东公司 抗凝血因子xi抗体
EP3554544A4 (en) * 2016-12-16 2020-07-29 Bluefin Biomedicine, Inc. ANTI-PROTEIN 1 ANTIBODY CONTAINING AN ANTI-CUB DOMAIN (CDCP1), ANTIBODY-DRUG CONJUGATES AND THEIR METHODS OF USE

Also Published As

Publication number Publication date
CA3118542A1 (en) 2020-05-14
CN113382750A (zh) 2021-09-10
EP3876988A4 (en) 2022-11-09
JP2022507294A (ja) 2022-01-18
EP3876988A1 (en) 2021-09-15
WO2020097336A1 (en) 2020-05-14
US20220119545A1 (en) 2022-04-21
AU2019376078A1 (en) 2021-06-03
JP7440509B2 (ja) 2024-02-28

Similar Documents

Publication Publication Date Title
MX2021005377A (es) Terapias dirigidas a cdcp1.
IL278920A (en) ENTPD2 antibodies, combination therapies, and methods of using antibodies and combination therapies
MX2020011746A (es) Terapias genicas para los trastornos lisosomales.
MX2020003939A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan los mismos.
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
PH12021550152A1 (en) Anti-cd112r compositions and methods
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
WO2018187227A8 (en) Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
MX2020011748A (es) Terapias genicas para los trastornos lisosomales.
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
JOP20200074A1 (ar) أجسام مضادة ضد tau واستخداماتها
MX2020010379A (es) Sistemas y metodos de procesamiento.
WO2018106776A3 (en) Anti-tau antibodies and methods of their use
MX2018013762A (es) Polipeptidos de fusion de ligando de cumulo de diferenciacion 40 y fragmento cristalizable (cd40l-fc) y sus metodos de uso.
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MX2022007994A (es) Derivados de arilciclohexilamina y su uso en el tratamiento de trastornos psiquiátricos.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
CA188476S (en) Sponge
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2020008408A (es) Imagenologia y terapia dirigidas por la granzima b.
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
AU2019321490A8 (en) Ox40-binding polypeptides and uses thereof
EP3585818A4 (en) ANTI-HLA-DQ2.5 / 8 ANTIBODIES AND ITS USE FOR THE TREATMENT OF C LIATIC DISEASE
AU2018262805A1 (en) Peptides for treatment of diabetes